Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty(Cancer Research Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Richard J. Lee(La Roche College), Grant A. McArthur(The University of Melbourne), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Antoni Ribas(University of California, Los Angeles), K. B. Nolop(Plexxikon (United States)), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Joseph F. Grippo(Inflarx (Germany)), Peter J. O’Dwyer(University of Pennsylvania)
Cited by 3,535
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k